Ritonavir/Lopinavir

Ritonavir/Lopinavir is a drug that inhibits the activity of cyclosporine and many other chemicals in the body.

It's approved for people with the human immunodeficiency virus to combat AIDS and those undergoing chemotherapy to prevent the risk of organ rejection following a transplant.

It is an antiviral drug that inhibits the enzyme atazanavir, which is necessary for the replication of HIV. It has been used in combination with azidothymidine (AZT) or zalcitabine to make their antiviral effects more potent against HIV's protease.

It was the lead inhibitor of atazanavir, which became a successful treatment for people infected with HIV-1 after being approved by the Food and Drug Administration on November 8th, 2010.

Ritonavir/Lopinavir is both a protease inhibitor and antiviral medication used in combination. The most common one is used in combination therapy to treat HIV, better known as antiretroviral therapy.

It is widely used to control the human immunodeficiency virus (HIV) infection after failure of first-line agents like azidothymidine (AZT). When used alone, its efficacy may be limited.

It is also prescribed as an adjunct treatment for HCV infection; evidence shows it can make treating HCV either more effective or less difficult, depending on the mutation type of the virus.

For hepatitis C regimens without interferon can lessen side effects caused by ribavirin (typically haemolytic anaemia).